<?xml version="1.0" encoding="UTF-8"?>
<p>By December 2014, several hundred patients were expected to take part in 3 separate trials in early 2015 conducted at Médecins Sans Frontières–run Ebola treatment centers in Guinea and Liberia. The different objectives are to test the administration of antibodies from the blood of Ebola survivors to neutralize EV in the patients (passive immunization) or to interfere with transcription and replication of the EV by using antivirals, which have shown promise in other viral diseases.</p>
